The shPRMT6 plasmid and control plasmid were purchased from GeneChem (Shanghai, China). PRMT6 overexpression plasmid and empty vector were obtained from Tsingke (Beijing, China). shYTHDF2 and shCDK9 plasmids, along with their respective control plasmids, and YTHDF2 and CDK9 overexpression plasmids, were also sourced from Tsingke (Beijing, China). YTHDF2 promoter-driven luciferase reporter gene plasmid and Renilla luciferase control plasmid were acquired from OBiO Technology (Shanghai, China). EPZ020411 was purchased from Cayman (USA), CHIR-99021 (Cat#HY-10182A) and Actinomycin D (Cat#HY-17559) were from MCE (USA). The anti-PRMT6 (Cat#14641) antibody was from CST (Boston, MA, USA). Antibodies against YTHDF2 (Cat#24744-1-AP), Cyclin D1 (Cat#60186-1-Ig), E-cadherin (Cat#20874-1-AP), and N-cadherin (Cat#22018-1-AP) were from Proteintech (Wuhan, China). Anti-βcatenin (Cat#PK02151), Vimentin (Cat#T55134) antibodies were from Abmart (Shanghai, China). Anti-pβ-catenin (Cat#sc-57535), GSK-3β (Cat#sc-53931) antibodies were from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-APC (Cat#WL02422), c-Myc (Cat#WL01781) antibodies were from Wanleibio (Shenyang, China). Anti-Histone H3R2me2a antibodies were from Genetex (USA, Cat#GTX54134) and PTM BIO (Hangzhou, China, Cat#PTM668). Anti-CDK9 antibodies were from Abcam (UK, Cat#ab239364) and Santa Cruz Biotechnology (USA, Cat#sc-13130x).